LONDON, March 27, 2024 (GLOBE NEWSWIRE) — Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited, has successfully conducted the world’s first bladder cancer sentinel lymph node (SLN) procedure using SENSEI ®, a revolutionary miniature robotic-assisted gamma probe. The groundbreaking surgery took place at Hospital del Mar in Barcelona, Spain, marking a significant advancement in cancer detection and treatment.
The SENSEI ® device, smaller than an AA battery, was specifically designed for robotic-assisted and minimally invasive surgery, making it ideal for intricate procedures such as those involving the bladder. Dr. LluÃs Cecchini, Head of Urology at Hospital del Mar, emphasized the importance of excising cancerous lymph nodes around the bladder, underscoring the potential impact of the innovative technology in enhancing surgical precision and patient outcomes.
SENSEI ®’s successful use in the bladder cancer surgery signifies a major milestone for Telix and Lightpoint, showcasing the device’s versatility and potential for expanding into other urologic malignancies. With its approved status for sale in key markets, including the US, EU, UK, and Australia, SENSEI ® is poised to revolutionize radio-guided surgery across various medical specialties and cancer types.
The procedure at Hospital del Mar demonstrates the transformative power of advanced medical technologies in improving the accuracy and efficiency of surgical interventions. As Telix continues to innovate and integrate SENSEI ® into its comprehensive oncology programs, the future of cancer diagnosis and treatment appears increasingly promising.
